Clinical Trial Failures 2026: AstraZeneca, Novartis and Kyowa Kirin Report a Wave of Phase 2 and Phase 3 Setbacks

Clinical Trial Failures 2026 has emerged as one of the year’s most closely watched storylines in biopharma, as four major companies disclosed studies that, in three of them, missed their primary endpoints within the same eleven-day window in September. AstraZeneca, Novartis, Kyowa Kirin, and Novo Nordisk each reported setbacks spanning breast cancer, cardiovascular disease, macular degeneration, and Alzheimer’s disease, underscoring how frequently late-stage development still falls short even when a drug appears to work at the biological level. Clinical Trial Failures 2026 reporting shows a pattern that recurs across therapeutic areas: a drug lowers a biomarker, slows a disease process, or shows a numerical trend in the right direction, yet the trial’s pre-specified statistical bar is not cleared.

The disclosures arrived through different regulatory channels, an inside-information notice under EU market abuse rules for AstraZeneca, a Swiss ad hoc announcement for Novartis, a topline data release for Kyowa Kirin, and a scheduled Phase 3 readout for Novo Nordisk, but all four converged on one conclusion: a well-designed, adequately powered study still returned a negative or inconclusive primary result. Between September 4 and September 12, 2026 alone, three of the four trials in this Clinical Trial Failures 2026 accounting were reported, joining a November 2025 semaglutide miss in Alzheimer’s disease that had already signaled how difficult neurodegenerative and cardiometabolic endpoints remain to hit.

The first entry in this Clinical Trial Failures 2026 list is AstraZeneca’s Phase III SERENA-4 trial, tested in 1,371 adult patients with hormone receptor-positive, HER2-negative advanced breast cancer, comparing Etcamah (camizestrant) plus palbociclib against anastrozole plus palbociclib in the first-line, treatment-naive setting. On September 11, 2026, the company disclosed that investigator-assessed progression-free survival did not reach statistical significance, even though a numerical benefit favored the Etcamah combination. Susan Galbraith, the company’s oncology research chief, said AstraZeneca was disappointed but would now focus on patients who already qualify for Etcamah through ESR1 mutation testing under the separate, already-approved SERENA-6 regimen.

That distinction matters clinically. SERENA-6 identifies resistance as it emerges and switches therapy proactively; SERENA-4 tried to make Etcamah a frontline replacement for aromatase inhibitors before resistance develops. AstraZeneca has not yet released the numerical progression-free survival values, hazard ratio, or confidence interval, saying only that additional data will follow at a future medical meeting. The safety profile was reported as unchanged from each medicine’s known individual profile, with no new signals identified.

Learn More

AstraZeneca Enhertu DESTINY-Lung04 Trial Demonstrates 14.3-Month Median PFS in First-Line HER2-Mutant NSCLC

Clinical Trial Failures 2026: The Root Causes Behind September’s Phase 2 and Phase 3 Misses

Looking across all four disclosures, the recurring root cause behind this round of Clinical Trial Failures 2026 is a disconnect between a measurable biological signal and a statistically significant clinical benefit. In SERENA-4, the numerical PFS trend favored Etcamah, but the effect size was not large enough to separate from the comparator arm with statistical confidence. Novartis encountered a similar disconnect on a larger scale: its Lp(a)HORIZON trial, run in 8,323 patients with elevated lipoprotein(a) and established cardiovascular disease, showed that pelacarsen successfully lowered Lp(a) levels, yet that reduction did not translate into fewer cardiovascular deaths, heart attacks, strokes, or urgent revascularizations, the trial’s four-part composite primary endpoint.

Shreeram Aradhye, Novartis’s chief medical officer, acknowledged the results were “not the results we hoped for,” while noting the data still advance the field’s understanding of how Lp(a) reduction relates to cardiovascular risk. Because Lp(a) is roughly 90% genetically determined and cannot be meaningfully changed through diet or lifestyle, pelacarsen represented one of the first hard-outcomes tests of whether lowering it pharmacologically actually protects patients, a hypothesis Clinical Trial Failures 2026 data have now left unresolved rather than confirmed.

Kyowa Kirin’s KHK4951 eye drops, built on the tyrosine kinase inhibitor tivozanib, illustrate a third variant of the same root cause: an absent dose-response relationship. Across three dosing regimens tested in patients with neovascular age-related macular degeneration, 65% to 69% of participants avoided vision loss or rescue treatment through Week 52, but the high dose failed to outperform the low dose, the specific comparison set as the primary endpoint. Novo Nordisk’s twin EVOKE and EVOKE+ trials, run in 3,808 patients with early Alzheimer’s disease, showed the starkest version: oral semaglutide improved Alzheimer’s-related biomarkers yet produced no statistically significant slowing of cognitive decline on the Clinical Dementia Rating scale, undercutting the metabolic hypothesis that GLP-1 drugs might treat neurodegeneration the way they treat diabetes and obesity.

Effect on Patients: What Clinical Trial Failures 2026 Means for People in Treatment

For patients enrolled in or waiting on these programs, Clinical Trial Failures 2026 translates into continued reliance on existing standards of care rather than immediate new options. Breast cancer patients newly diagnosed with advanced HR-positive, HER2-negative disease will continue starting on aromatase inhibitors plus a CDK4/6 inhibitor rather than Etcamah, reserving the newer drug for after ESR1 mutation testing detects resistance. Patients with elevated Lp(a) and existing cardiovascular disease still have no approved targeted therapy, despite guidelines in the US and Europe recommending that every adult be tested for the biomarker at least once.

nAMD patients, who currently require repeated intravitreal anti-VEGF injections to preserve vision, will not see an eye-drop alternative reach the market soon, even though Kyowa Kirin’s data suggest encouraging retention of visual acuity through one year, with dry eye and punctate keratitis as the only notable tolerability findings and no blood-pressure signal despite the VEGF-pathway mechanism. For the 3,808 people enrolled in EVOKE and EVOKE+, oral semaglutide was safe and well tolerated but did not measurably slow their disease, a result Novo Nordisk’s head of research and development described as disappointing while affirming the trials met rigorous methodological standards. This is the most direct patient cost across the Clinical Trial Failures 2026 dataset: none of the four disclosures reported new safety signals, so patients already taking these medicines for approved indications see no change, but none gain a new option either.

Learn More

TEZSPIRE Eosinophilic Esophagitis Trial: Amgen, AstraZeneca Report Positive Phase 3 CROSSING Results

Delays and Development Timelines Reshaped by Clinical Trial Failures 2026

Each company has pushed key decisions further out rather than ending its program outright, a pattern typical of Clinical Trial Failures 2026 at the Phase 2 and Phase 3 level. AstraZeneca has not set a date for releasing full SERENA-4 hazard ratios and confidence intervals, deferring that transparency to an unspecified future medical congress while its CAMBRIA-1 and CAMBRIA-2 trials, covering roughly 10,000 patients in earlier-stage breast cancer, continue unaffected. Novartis likewise withheld the complete Lp(a)HORIZON dataset, promising a presentation at an upcoming cardiology congress and declining to specify any regulatory filing timeline for pelacarsen.

Kyowa Kirin said it needs more time to evaluate what the anatomical and safety findings from Study 4951-002 mean for a future, more rigorously controlled trial design, while its separate Phase 2 diabetic macular edema study, 4951-003, continues in parallel. Novo Nordisk drew a firmer line, stating plainly that semaglutide did not demonstrate efficacy in Alzheimer’s disease, closing that indication rather than delaying it, even as the company’s core diabetes and obesity franchise advances separately. Across all four Clinical Trial Failures 2026 cases, undisclosed granular data represent the clearest near-term bottleneck: regulators, physicians and investors cannot fully assess risk-benefit until hazard ratios, confidence intervals, and subgroup analyses are published.

The Broader Trend Behind Clinical Trial Failures 2026

Taken together, Clinical Trial Failures 2026 point to a broader trend of biomarker-outcome disconnects across therapeutic areas that were each considered scientifically promising going in. Lp(a) lowering, ESR1-directed endocrine switching, tivozanib eye drops, and GLP-1 neuroprotection were each grounded in credible mechanistic rationale, yet each stumbled at the final statistical hurdle that separates a plausible hypothesis from an approvable therapy. Novo Nordisk’s stock fell approximately 9% to 12% on its Alzheimer’s news alone, illustrating how financial markets treat a single Phase 3 miss as a meaningful repricing event even for a company with an otherwise dominant franchise.

None of the four companies has abandoned its broader pipeline strategy. AstraZeneca is layering saruparib and Datroway combinations around Etcamah; Novartis is reaffirming a four-decade cardiovascular research commitment; Kyowa Kirin is continuing its tivozanib eye-drop program in a second retinal indication; and Novo Nordisk says its semaglutide safety and efficacy record in diabetes and obesity remains intact. Clinical Trial Failures 2026, in that sense, reads less as abandoned science and more as a reminder that even well-funded, well-designed late-stage trials fail to convert biological plausibility into proven patient benefit more often than breakthrough headlines suggest.

Summary of Reported Trial Failures

Trial Design and Patient Population

Endpoint Status and Disclosure Gaps

Company Response and Pipeline Status